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From the
Desk of the
Residency
Program
Director

To Friends of the Department of Medicine
Our program continues to train the best and brightest residents in the
country. As we complete another challenging academic year marred by
the ongoing fight against gun violence in Philadelphia and across the
United States, the opioid pandemic and the ever present threat of another
COVID-19 surge our residents have continued to rise to every challenge
and thrive as physicians. During the three years we are fortunate to have
them at our program, it is my distinct pleasure to watch them grow into
confident, dedicated, compassionate clinicians. The residents are not just
outstanding clinicians but excel in all aspects of medicine including
research, humanities and medical education.
This will be my last year writing to all of you as the Program Director. As
I move on to new career challenges, I leave Jefferson with hope and
gratitude for the future of medicine. The exceptional altruism and
dedication portrayed by our colleagues is unmatched. Despite the
challenges, they have treated every patient with grace and poise working
alongside faculty to support the Jefferson mission: We Improve Lives. In
the midst of the chaos, our residents have still completed research,
quality improvement projects and contributed to the humanities. This
publication is just one example of the passion, dedication and creativity
our residents continue to provide to the Jefferson Community.
This journal, now in its 23th edition, continues to exemplify the
perseverance, inquisitiveness and talent of our Internal Medicine residents.
Congratulations to the Editors and all of the residents who contributed to
another amazing edition of the Forum. I hope you will enjoy reading it!
Emily Stewart, MD, FACP
Associate Professor of Medicine
Program Director Internal Medicine Residency
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From the
Editors

Dear Students, Residents, Fellows, Faculty, and Friends of the Forum,
It is our honor to present the 23rd Annual edition of The Medicine Forum to the
Jefferson community. With all the uncertainties and stressors that exist both inside and
outside of the hospital walls, it is truly remarkable to see the quality of contributions
by our authors. From the multitude of case reports to the collection of artworks, our
residents have generated an array of unique and interesting work. We hope that this
edition will continue to honor the tradition of The Medicine Forum, which is the
celebration of scholarly activity among physicians in training at our institution.
Sincerely from the Editorial Board,
Shuji Mitsuhashi, MD
Abdul Kazi, MD
Matthew DiMeglio, DO, MBA

Editorial
Staff

Sean Dikdan, MD

Alexander Hajduczok, MD

Zachary French, MD

Rebecca Loh, MD

Jonathan Glatt, MD

Friends of
The Forum

Mark S. Berger, MD

Dipti S. Pancholy, MD

Jane R. Eisner

Alan H Wang, MD

Anna T. Monias, MD

Shiela Wang, MD
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FROM
the CHIEF
ResidentS

To the Residents,
The four of us have had the unique opportunity to work alongside you and watch you
grow throughout the last three years. During an extremely turbulent time at Jefferson, in
the city of Philadelphia, and the larger healthcare landscape you all have been the
constant presence that has kept the Jefferson IM residency culture alive.
Jefferson residents are: Compassionate, intelligent, dedicated, fun, and resilient. But
most of all, Jefferson residents look out for each other and have each other’s backs. This
is the culture that brings people to our program and the culture that makes residency
training which would otherwise be grueling into a manageable, and at times, fun
experience. You all have embodied this culture, and we as well as the residency program
are so grateful to each and every one of you.
While it is sad that we are now parting ways, we are so proud to have called you all
colleagues during these crazy years, and we could not imagine a better group of people
to have gone through this with than you. It’s been an honor and a privilege to be your
Chieves this year. We cannot wait to work alongside you and see all that you will
accomplish in your careers. Cheers to you all!
Sincerely,
Cristina Angelo, MD
Katie Duffey, MD
Evan Nardone, MD
Michelle Perkons, MD

Left to right:
Michelle Perkons, MD,
Evan Nardone, MD,
Cristina Angelo, MD,
Katie Duffey, MD
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CARDIOLOGY

Challenges of Managing Giant Cell Myocarditis: A
Case Report on the Mechanical Support Perspective
Abdul W Kazi, MD, MBA1, Harsh Doshi, MD2
1. Division of Hospital Medicine, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2. Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

INTRODUCTION
Giant cell myocarditis is a rare and fatal disease which
may result in heart failure, complete heart block, or
ventricular arrhythmias. We describe a patient who
previously had been discharged from our institution
with a left ventricular assist device and immunosuppressive therapy for management of his giant cell
myocarditis. His subsequent course was complicated
by further deterioration of heart function which required
multiple mechanical circulatory support devices. He
successfully received a heart transplant which later had
recurrence of giant cell myocarditis. This case highlights
the challenges of left and right sided mechanical assist
devices in managing giant cell myocarditis.

CASE PRESENTATION
AG is a 33-year-old Hispanic man with a history of heart
failure with reduced ejection fraction secondary to
giant cell myocarditis implanted with a HeartMate3 left
ventricular assist device (LVAD) who presented after
experiencing low flow alarms.
The patient presented with a three-week history of
diffuse abdominal pain and low-flow alarms on his
LVAD. Device parameters were as follows: flow of 3.3 L/
min, speed of 5500 rpm, PI of 4.2, and Power of 3.9
Watts. Echocardiography was significant for right
ventricular dilation and hypertrophy and severely
decreased right ventricular function. CT abdomen/
pelvis showed hepatic venous congestion and a
thick-walled descending colon. There were new findings
of fluid overload with new pleural effusions, ascites, and
anasarca. The patient was admitted due to worsening
right heart failure and increasing inotrope requirements.
He also tested positive for SARS COV-2 on admission
PCR testing despite being asymptomatic and afebrile.
Right heart catheterization showed RA pressure of
25mmHg, RV 30/25 mmHg, PA 30/25/28, PCWP
25mmgHg with a CO of 2.7, CI of 1.5, SVR of 2516, and
PVR of 1.1. The patient was started on milrinone for
inotropic support. He also began workup for right
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ventricular assist device as a bridge to heart transplantation and received a CT angiogram which showed
scarring of R IJ from a prior Protek Duo temporarily
placed on a previous admission. This resulted in
unfavorable subclavian anatomy for a new Protek Duo.
Due to concern for worsening RV dysfunction, RHC
was repeated five days later which showed RA
27mmHg, PA 34/23, PCWP 23 with CI of 1.57, CO of
2.87, PVR of 1.04, and SVR of 2033. Milrinone dose was
increased and dobutamine was added. The patient
continued to clinically deteriorate so an Impella RP
was placed One day after placement of the device, AG
had darkening of his urine, elevated LDH, and decreased
hemoglobin and platelet count, consistent with deviceinduced hemolysis. A subsequent right IJ angioplasty
was performed to allow for placement of a Protek
Duo. The patients undocumented immigration status
had in the past resulted in limited opportunities for
transplantation, however acquisition of health
insurance since then allowed for the patient to be a
candidate for an orthotropic heart transplant.

DISCUSSION & KEY POINTS
Giant cell myocarditis (GCM) is a rare and fatal disease
resulting in significant mortality due to heart failure,
complete heart block, and ventricular arrhythmias.
Patients with GCM often present at middle-age in
fulminant heart failure or arrythmias, and early diagnosis
is critical for management. Even for patients diagnosed
with GCM during their lifetimes and managed with
immunosuppressive therapy, transplant-free survival at
5-years is only 48%1. While the pathophysiology of GCM
is not entirely understood, it is characterized by
T-lymphocyte myocardial inflammation that can be
diagnosed on gold-standard endomyocardial biopsy2.
Diffuse myocardial inflammatory infiltrates with multinucleated giant cells can also be targeted for biopsy with
cardiac MRI assistance. Imaging findings are consistent
with myocardial fibrosis; there is myocardial strain and
late-gadolinium enhancement visible at affected areas
of the myocardium3.
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Immunosuppression of T-mediated inflammation with
prednisone, azathioprine, and cyclosporine can mitigate
the disease and improve survival. Patients should also
be optimized with goal directed medical therapy for
heart failure, but unstable hemodynamic presentation
can limit the extent of medical management. Despite
immunosuppression and medical management,
mortality is high and serious ventricular tachycardias
continue to be the single most prominent reason for
death in patients with GCM4. Immunosuppression and
ICD placement are mainstays of GCM therapy, but this
report focuses on mechanical circulatory support
(MCS) devices and their role in GCM management.
There are a variety of options for MCS when managing
GCM. These options can be temporary or durable, but
destination therapy is limited to orthotopic heart
transplant. The decision for types of MCS can be
influenced by the patient's clinical status, degree of
cardiac dysfunction, institutional preferences, and
patient’s listing status for transplant. Because of the rare
and fulminant presentation of GCM, it is common for
patients to be severely symptomatic prior to
biopsy-proven diagnosis. In one case series of seven
GCM patients the time interval from referral to device
placement or transplant ranged from 2 days to 4
months, and GCM was not diagnosed in any patient
prior to intervention5. There is favorable evidence for
VA-ECMO as the first temporary MCS option 6 . In
addition to ECMO, intra-aortic balloon pumps (IABP) or
other trademarked devices are feasible as temporary
bridge-therapy. More durable MCS options include
LVAD, BiVAD, or total artificial heart (TAH) implants.
In the case of AG, the patient had a previous admission
with right ventricular dysfunction requiring a Protek
Duo RVAD. The Protek Duo Cannula has been shown
to be a safe and effective option for short term
Bi-Ventricular support in conjunction with a secondary
LV device7. This is a dual lumen cannula device percutaneously inserted via the internal jugular vein and
positioned to have the inflow lumen in the right atrium
and the outflow lumen positioned in the main
pulmonary artery. A disadvantage of short-term
percutaneous RV assist devices is the possibility of
venous scarring resulting in difficulty of device
re-insertion. For AG, venous angioplasty was a safe and
effective technique to allow for Protek Duo re-insertion
in a patient with unfavorable anatomy who has failed
Impella RP placement.

GCM recurrence after transplant despite continuing
immunosuppressive therapy8. The rarity, severity, and
acuity of giant cell myocarditis results in limited ability to
conduct randomized control trials. Despite these
barriers to establishing better evidence-based
management, the use of MCS, and immunosuppressive
therapy are still cornerstones of therapy as bridgetherapy to cardiac transplantation.

REFERENCES
1. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K,
Kupari M. Long-term outcome and its predictors in giant cell myocarditis.
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journal of the United States and Canadian Academy of Pathology, Inc. 1996.
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4. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J,
Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis
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2013;6(1):15–22.
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LT. Long-term risk of recurrence, morbidity and mortality in giant cell
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After hemodynamic stabilization, AG was able to
successfully receive an OHT. His clinical course was
then complicated by recurrence of GCM. Studies have
shown that approximately 12% of patients can have
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CARDIOLOGY

Another Case of Takotsubo Syndrome: Excluded by
the Presence of Significant Coronary Artery Disease,
or Caused by Significant Coronary Artery Disease?
Bharaniabirami Rajaram, MD1, Neveda Murugesan, MD1, Gregary D. Marhefka, MD2
1. Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2. Division of Cardiology, Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

Figure 1: ECG on presentation. 1-2 mm ST-segment elevations and T wave inversions in V4-V6, consistent with a lateral STEMI.

INTRODUCTION
Takotsubo syndrome (TTS) is a reversible condition of
abnormal myocardial contraction that was first given this
name in Japan by Dr. Sato in 1991.1 The name comes
from the Japanese word for “octopus trap,” which has a
similar shape to that of the left ventricle on ventriculography during Takotsubo syndrome. It is also known as
broken heart syndrome, stress-induced cardiomyopathy,
or apical ballooning syndrome. The first descriptions of
this phenomenon date as far back as the 1960s.2-3
TTS typically presents with symptoms and clinical signs
suggestive of acute coronary syndrome (ACS). It may
include ST segment elevations on electrocardiogram
(ECG) characteristic of acute ischemia even though the
syndrome is not caused by direct myocardial ischemia.
On echocardiography, TTS is usually characterized by
segmental wall motion abnormalities (SWMA) with
hyperdynamic contraction of the left ventricular basal
walls and akinesis of the apical walls. This results in the
“apical ballooning” and is notably not in the distribution
of typical coronary artery anatomy.4 Traditionally, the
diagnosis of TTS involves the aforementioned findings
and coronary angiography showing no obstructive
coronary artery disease (CAD).5 We present here a case
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of an acute lateral ST-elevation myocardial infarction
(STEMI) with subsequent cardiogenic shock due to TTS.

CASE PRESENTATION
History of Present Illness
A 68-year-old Caucasian female smoker without
significant cardiac history presented to the emergency
department of a suburban hospital with three days of
progressive abdominal pain, initially thought to be a
recurrence of her peptic ulcer disease. She described
the pain as sharp and constant without radiation. She
attempted to take over-the-counter antacids without
any relief. She denied other symptoms such as
dyspnea, chest pain, or palpitations. Physical exam at
that time was unremarkable. Chest x-ray was did not
show pulmonary edema or consolidation. Labs at the
outside facility were notable for elevated troponin I at
3.18 ng/mL and lactate at 4.3 mmol/L. Her ECG
showed ST elevations and terminal T wave inversions
in laterals leads (I, aVL, and V4-V6) consistent with a
lateral STEMI (Figure 1). The patient was transferred to
our facility for emergent cardiac catheterization and
cardiac intensive care.
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Hospital Course

DISCUSSION

Upon arrival at our facility, the patient underwent coronary
angiography, which revealed the culprit lesion was a
100% occlusion of the second obtuse marginal branch of
the left circumflex artery . The left main, left anterior
descending, and right coronary arteries were found to
have only minimal luminal irregularities. A drug-eluting
stent was successfully placed and resulted in 0% residual
stenosis. Notably, LV end diastolic pressure was elevated
at 34 mmHg. She was then transferred to the cardiac
intensive care unit for further management. Physical
exam was notable for bilateral crackles on lung
auscultation. Repeated chest x-ray done five hours from
initial image showed new bilateral hazy opacities,
consistent with pulmonary edema. She was given
intravenous (IV) tirofiban, oral dual anti-platelet therapy,
high intensity statin, and IV furosemide. Beta-blocker and
angiotensin converting enzyme inhibitor (ACEi) therapies
were not initiated due to acute heart failure with mild
hypotension (systemic blood pressure 100s/60s).

The diagnosis of TTS is typically made with signs and
symptoms of ACS, regional wall motion abnormalities
on echocardiography, and the absence of an
obstructive culprit lesion on coronary angiography.
Bybee et al. proposed the Mayo criteria, which mandate
that there is no angiographic evidence of obstructive
coronary disease or plaque rupture.5 Other similar
criteria have been proposed, and all include the
exclusion of obstructive coronary disease and acute
coronary thrombus.6,7

The patient continued to have intermittent chest
discomfort and nausea, without evidence of worsening
myocardial ischemia. Serial ECGs showed resolution of
ST segment elevations and persistent T-wave inversions.
However, repeated lactate was higher than previous and
peaked at 6.5 mmol/L. Liver enzymes also increased
triggering suspicion for shock liver. Post-intervention
transthoracic echocardiogram (TTE) demonstrated a
severely reduced left ventricular ejection fraction (LVEF)
of 34%, with SWMAs, apical akinesis, and ballooning of
the LV apex. Notably, as seen in some cases of TTS, there
was no left ventricular outflow tract (LVOT) obstruction
or increased intracavitary gradient due to hyperkinesis of
the basal segments in this patient. These TTE findings
were significantly disproportionate to the relatively small
territory of SWMAs expected from her lateral STEMI and
more consistent visually and clinically with TTS.
The patient required inotropic support with IV dobutamine
in the setting of worsening end organ perfusion from
cardiogenic shock. She was also continued on regular IV
diuretics for volume status optimization. Status of her
cardiogenic shock was not monitored with invasive
hemodynamic monitoring, but end organ function was
trended closely with serial lactate levels, liver enzymes,
and creatinine. On the fifth day of hospitalization, she
was successfully weaned off of dobutamine and was
transferred from the intensive care unit to the general
telemetry floor. TTE on this day showed recovery of LVEF
to 60%, with focal inferolateral and anterolateral wall
hypokinesis, and there was resolution of the periapical
wall motion abnormalities.
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The pathophysiology of TTS remains poorly
understood, though there have been several proposed
mechanisms and theories. The most widely accepted
explanation is that increased systemic catecholamine
levels lead to decreased LV function through
microvascular spasm causing transient ischemia, as
well as direct cardiotoxicity. 4,6 Emerging data also
suggests that there is a role for endothelial dysfunction
and estrogen deficiency, resulting in epicardial and/or
microvascular spasm.8 This could partially explain the
higher prevalence of TTS in post-menopausal women.
More recently, however, cases of concurrent TTS and
MI have been described, suggesting that the
co-existence of the two are not exclusionary, as once
thought.9,10 Adding to this small collection, we describe
a case in which apical LV dysfunction was significantly
disproportionate to the area of lateral infarction.
Ultimately, resolution of the SWMAs supports the
diagnosis of TTS. Some recent reports also suggest
that transient apical LV wall thickening due to
myocardial edema is a characteristic feature in the
subacute recovery phase of TTS. This was not
appreciated in the recovery echocardiogram obtained
in this patient, but T2 weighted cardiac magnetic
resonance imaging (MRI) may be a more sensitive
modality to assess this.11
Our case demonstrates that an acute MI can be
associated with and in this case, cause a stress response
that leads to TTS. TTS and acute MI are not mutually
exclusive and in certain cases should not be classified
as such. If a patient with a seemingly small infarct
develops cardiogenic shock, TTS should be considered
in the differential diagnosis and can typically be
discerned with TTE and managed expectantly.

The Medicine Forum, Volume 23 | 9 5 11

The Medicine Forum, Vol. 23 [2022], Art. 1

REFERENCES
1. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. [Myocardial stunning due
to simultaneous multivessel coronary spasms: a review of 5 cases].
J Cardiol. 1991;21(2):203-14. Japanese.
2. Parkes, C M et al. “Broken heart: a statistical study of increased mortality
among widowers.” British medical journal vol. 1,5646 (1969): 740-3.
3. Cebelin, M S, and C S Hirsch. “Human stress cardiomyopathy. Myocardial
lesions in victims of homicidal assaults without internal injuries.” Human
pathology vol. 11,2 (1980): 123-32.
4. Kato, K et al. “Takotsubo syndrome: aetiology, presentation and treatment.”
Heart (British Cardiac Society) vol. 103,18 (2017): 1461-1469.
5. Bybee, K A et al. “Systematic review: transient left ventricular apical
ballooning: a syndrome that mimics ST-segment elevation myocardial
infarction.” Annals of internal medicine vol. 141,11 (2004): 858-65.
6. Wittstein, I S et al. “Neurohumoral features of myocardial stunning due to
sudden emotional stress.” The New England journal of medicine vol. 352,6
(2005): 539-48.
7. Redfors, B et al. “Stress-induced cardiomyopathy (Takotsubo)--broken heart
and mind?” Vascular health and risk management vol. 9 (2013): 149-54.
8. Naegele, M et al. “Endothelial function and sympathetic nervous system
activity in patients with Takotsubo syndrome.” International journal of
cardiology vol. 224 (2016): 226-230.
9. Hussain, M A et al. “Apical ballooning (takotsubo) syndrome with
concurrent ST-segment elevation myocardial infarction.” BMJ case reports
vol. 2017 bcr2017220145. 24 Jul. 2017
10. Messas, N et al. “Takotsubo cardiomyopathy triggered by ischemic injury:
When lateral myocardial infarction precipitate apical ballooning syndrome.”
International journal of cardiology vol. 202 (2016): 858-60.
11. Izgi, Cemil et al. “Myocardial edema in Takotsubo syndrome mimicking
apical hypertrophic cardiomyopathy: An insight into diagnosis by cardiovascular magnetic resonance.” Heart & lung: the journal of critical care
vol. 44,6 (2015): 481-5.

10 | The Medicine Forum, Volume 23 5
https://jdc.jefferson.edu/tmf/vol23/iss1/1

12

et al.: The Medicine Forum: Volume 23

CARDIOLOGY

Cardiac Amyloidosis: A Known Disease with an
Unknown Presentation
Svenja Schneider, MD1, Tudor Sturzoiu, MD1, Tanuka Datta, MD2, Yevgeniy Brailovsky, DO, FACC2,
Sung-Hae Cho, MD, FACC2, Paulina Gorodin Kiliddar, MD2
1. Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
2. Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

ABSTRACT
Cardiac amyloidosis is an increasingly recognized entity
that causes significant morbidity and mortality.
Transthyretin amyloidosis (ATTR) is present in about 16%
of patients with severe aortic stenosis and up to 17% of
patients with heart failure with preserved ejection
fraction9,10. Though the screening test of choice, echocardiography is not highly sensitive or specific, and it should
not be relied upon to rule out cardiac amyloidosis,
especially if clinical suspicion is high.
We present a case of a 58-year-old woman with a history
of bilateral carpal tunnel syndrome who presented with
paresthesia and syncope. Extensive workup for
neurologic, infectious, and malignant etiologies was
negative. EKG was remarkable for low voltage.
Transthoracic echocardiogram (TTE) was not suggestive
of infiltrative disease. Subsequent cardiac MRI
demonstrated diffuse biventricular late gadolinium
enhancement and technetium 99M pyrophosphate scan
revealed diffuse (3+) uptake, which was in stark contrast
to the TTE. The diagnosis of ATTR amyloidosis allowed
for prompt initiation of treatment in this patient.
Syncope is an uncommon presentation of cardiac
amyloidosis. Such significant cardiac burden of disease
without appreciable changes on TTE or clinical heart
failure, demonstrates the importance of clinical vigilance
and thorough workup when suspicion for amyloidosis is
high, particularly if characteristic signs and symptoms
consistent with systemic disease are present, as timely
treatment can significantly reduce the morbidity and
mortality of this disease.

INTRODUCTION
The term “amyloidosis” describes a group of diseases
characterized by the tissue deposition of amyloid fibrils
- misfolded proteins or protein fragments that have
aggregated and stabilized in primarily beta-pleated sheet
configuration.1 When this process involves cardiac tissue,
it is known as cardiac amyloidosis. The subsets of amyloid
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most known for cardiac involvement are transthyretin
amyloidosis (ATTR) and light chain amyloidosis (AL).
Diagnosis of these diseases can be challenging as
echocardiographic parameters lack specificity and
sensitivity. Understandably, the involvement of cardiac
tissue carries a high morbidity and mortality rate, making
it an area of growing interest and research to this day. In
this case report, we highlight a patient with cardiomyopathy caused by ATTR and emphasize the importance
of maintaining a high index of suspicion for this disease.

CASE PRESENTATION
A 58-year-old female of Irish descent with a history of
bilateral carpal tunnel syndrome and bilateral lower
extremity paresthesias presented to the cardiology office
with complaint of recurrent syncope. She had undergone
an extensive evaluation by her primary care doctor and a
neurologist. With negative workup, but continued
episodes of syncope, she was referred to cardiology.
Her EKG was significant for low voltage and poor R-wave
progression (Figure 1). Her review of systems revealed a
15-pound unintentional weight loss over the previous
year, in addition to her paresthesias. Her family history
was significant for a paternal grandfather who died of
cardiac causes of unknown etiology. She had a normal
stress echo 4 months prior to evaluation. Labs were
unremarkable aside from a mildly elevated ferritin of 207
ng/mL (reference range 15-150 ng/mL).
A transthoracic echo showed normal left ventricular size
and systolic function. Concentric remodeling but no left
ventricular hypertrophy was present and there was
borderline left atrial enlargement. Although there were
technical limitations that precluded accurate assessment
of global longitudinal strain, the overall strain was
reduced but was not consistent with any diagnostic
pattern. Assessment of diastolic function revealed a
mildly reduced medial annular velocity of 6 cm/s but the
lateral annular velocity was normal measuring 11 cm/s
and the E/E ‘ was normal.
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Figure 1: Patient’s electrocardiogram showing low voltage and poor R-wave progression

Given suspicion for infiltrative disease due to the patient's
peripheral neuropathy and low voltage EKG, a cardiac
MRI was ordered. The MRI showed patchy late gadolinium
enhancement of the entire left ventricle involving
portions of the subendocardium, mid-myocardium and
subepicardial left ventricle, with additional enhancement
of the right ventricle (Figure 2). These findings were
highly concerning for amyloidosis and the diagnosis was
confirmed by nuclear medicine scanning, which showed
diffuse 3+ uptake of technetium 99 M pyrophosphate
throughout the myocardium, consistent with TTR
amyloidosis (Figure 3). To complete the workup, serum
and urine immunofixation electrophoresis were checked,
which were unremarkable.
Genetic testing confirmed the diagnosis of hereditary
amyloidosis with a T80A mutation. At time of diagnosis
her NT-proBNP was 331. She has since started on
tafamidis and patisiran, which she is tolerating well. She
currently has no clinical signs or symptoms of heart
failure. She has consulted both with a heart failure
specialist and a hepatologist regarding transplantation,
which are not indicated at this time. She has a large
extended family, and she has been educated on the
importance of considering genetic and phenotype
testing for them.

DISCUSSION
Transthyretin is a protein synthesized in the liver, that
normally exists as a tetramer whose main functions
include transport of vitamin A and thyroxine. There are
two types of ATTR: hereditary (ATTR-FAP) and wild-type
(ATTR-wt). ATTR-FAP is caused by inherited point
mutations of the transthyretin protein, of which over 100
have been identified, leading to accelerated amyloid
deposition. It usually displays autosomal dominant
inheritance. ATTR-wt (previously known as senile or
age-related systemic amyloidosis), is caused by normal
TTR that becomes unstable, misfolds, and accumulates
over time as amyloid deposits1,2.
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Figure 2: Cardiac MRI showing patchy late gadolinium enhancement of the entire
left ventricle involving portions of the subendocardium, mid-myocardium and
subepicardium

Figure 3: Nuclear PYP scan showing diffuse 3+ uptake

Due to the wide range of symptoms that ATTR can
cause in different organ systems, its diagnosis is not
straightforward and often delayed by years. Outside of
the heart, amyloidosis can present with progressive
symptoms in the nervous systems, eyes, kidneys, and
gastrointestinal tract. The most common initial symptoms
of ATTR-FAP are sensory-motor, such as peripheral
neuropathy and carpal tunnel syndrome, and autonomic,
such as GI motility disturbances and orthostatic
hypotension. These manifestations can pre-date the
diagnosis of amyloidosis by years3.
Although there are characteristic findings on EKG such
as low voltage and high-grade AV block, these are often
not present and is usually a late manifestation of cardiac
disease. In fact, less than 40% of patients with
biopsy-proven ATTR have low voltage on EKG4. The
first screening tool for diagnosis is most commonly a
transthoracic echocardiogram (TTE). There are several
characteristic TTE findings associated with cardiac
amyloidosis. The most referenced phenotype is
characterized by septal and left ventricular hypertrophy,
usually with diastolic dysfunction and preserved to low
ejection fraction. It is important to note that these
characteristics are not specific to amyloidosis.
Hypertrophic or hypertensive cardiomyopathy can
have overlapping echocardiographic features. However,
there have been some established studies showing
more unique differentiating features. For example,
two-dimensional speckle-tracking to show a relatively
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sensitive and specific “apical sparing” longitudinal strain
pattern is unique to amyloid cardiomyopathy5,6.

treatment with tafamidis and patisiran early in her
disease course.

If echocardiogram findings are suggestive of, or the
clinical suspicion is high enough for cardiac amyloidosis,
the next steps in workup include ruling out AL amyloidosis
and in some cases obtaining a cardiac MRI. Once AL is
ruled out, bone tracer cardiac scintigraphy is done to
assess for ATTR. Endomyocardial biopsy is only needed if
the scintigraphy grade is not sufficient to be diagnostic.
Once the diagnosis of ATTR is made, genetic testing is
used to identify hereditary ATTR5. This is particularly
important because family members can be screened.

ATTR has previously been considered a rare diagnosis.
However, recent studies suggest that ATTR is present in
about 16% of patients with severe aortic stenosis and up
to 17% of patients with HFpEF 9,10. This represents a
significant percentage of patients with these two fairly
common conditions, making accurate and early diagnosis
even more crucial, especially given that pharmacologic
therapies are most effective when initiated prior to the
onset of significant cardiac involvement.

The treatment of cardiac amyloidosis is a continuously
evolving field with the most recent developments being
disease-modifying agents such as TTR stabilizers,
silencers, and disruptors. Liver transplantation is an
option to stop the progression of disease though it does
not reverse already existing amyloid infiltration and
related symptoms and is becoming less common as
medical therapies improve7,8.
In this case, we demonstrate how cardiac amyloidosis
can have a varied presentation, requiring prompt
recognition and diagnosis. Although TTE is the first
screening test of choice, its imperfect sensitivity and
specificity do not allow it to be used to rule out a diagnosis
of CA. One must maintain a high index of suspicion and
pursue further testing especially in situations where other
organ systems are already involved2. Our patient had a
history concerning for CA given her peripheral
neuropathy, bilateral carpal tunnel syndrome, and
syncopal episodes. She had low voltage on EKG but her
TTE was not suggestive of infiltrative disease.
The patient’s TTE was a stark contrast to the cardiac MRI
and PYP scan, which showed extensive late enhancement
and diffuse 3+ uptake throughout the myocardium,
respectively. Such significant cardiac burden of disease
without appreciable changes on TTE further demonstrates
the importance of clinical vigilance and thorough workup
when suspicion for amyloidosis is high.
Early detection is especially important given the
progressive nature of ATTR and the fact that there are
therapies with multiple different mechanisms of action
available to halt the progression of this disease. These
medications are most effective at minimizing the
impact of the disease when initiated early, as the
compounding effects of this disease over time are not
reversible with pharmacologic therapy. Furthermore,
cardiac involvement, when present, is the principal
determinant of survival5. Our patient’s diagnosis was
fortunately confirmed before she had any significant
heart failure symptoms, and she was initiated on
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In conclusion, this case serves to emphasize the
variation of clinical presentation in ATTR and specifically
the limited sensitivity of echocardiography in diagnosis.
It remains of high importance to consider and act early
when there is clinical suspicion for amyloidosis in
patients with a compatible history.
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A Case of Patent Foramen Ovale as a Cause of
Persistent Hypoxia
Jaya Janadhyala, MD1, Jonathan Foster, MD1
1. Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

INTRODUCTION
Patent foramen ovale (PFO) is a congenital cardiac
variant caused by failure of the closure of a passage in
the atrial septum. It is quite common, occurring in as
much as 27% of the population based on autopsy
studies.1 Most cases of PFOs are incidentally discovered
or found during work-up of cryptogenic strokes as a
potential cause of the stroke.1 New research is being
conducted on the role PFOs play in hypoxia from
intracardiac right-to-left shunting, including in patients
with co-existent cardiovascular and pulmonary disease.2

CASE PRESENTATION
A 52-year-old man with a past medical history of heart
failure with reduced ejection fraction (EF 15%) from
non-ischemic cardiomyopathy now status post single
chamber ICD placement, atrial flutter, and chronic kidney
disease presented for worsening hypoxia and bilateral
lower extremity edema. Patient acknowledged worsening
dyspnea on exertion, orthopnea, and lower extremity
edema over the four weeks prior to admission. Other
review of systems was negative. Vital signs upon
presentation were significant for low blood pressures
(90s/50s), tachypnea to mid-20s, and SaO2 88% on 6 L
nasal cannula oxygen. Physical exam was significant for
elevated JVP, bilateral pitting lower extremity edema,
bibasilar crackles up to mid lung fields bilaterally, clubbing
of fingernails, and a holosystolic 3/6 murmur. Labs were
significant for an acute kidney injury with a creatinine of
2.06 (from baseline 1.7) and proBNP of 7444. Initial right
heart catheterization showed elevated filling pressures
(RA 15 and PCWP 22). Patient was aggressively diuresed
with a furosemide drip with no improvement in hypoxia.
Increasing the patient’s nasal cannula from 6 L to higher
levels also did not improve the hypoxia.

DIFFERENTIAL DIAGNOSIS
The differential could include hypoxia secondary to an
exacerbation of the patient’s heart failure and pneumonia.
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However, the patient’s hypoxia did not improve with
aggressive diuresis, and the patient did not have any
clinical symptoms of pneumonia. Work-up was initiated
for patent foramen ovale as a cause of persistent hypoxia.
Due to a concern for a shunt, right heart catheterization
was repeated with a wedge saturation that did show
some degree of shunting. A positional ABG showed a
PO2 of 111 mmHg while lying and 72 mmHg while
sitting upright. A TEE at that time showed a 6 mm PFO
with significant R to L shunt. At this point, work-up was
started for possible closure of PFO.

OUTCOME AND FOLLOW-UP
Due to a difficult social situation, including poor family/
social support and uninsured status, decision was made
for patient to complete work-up for PFO closure after
discharge with social work’s assistance and follow-up at
structural heart clinic. Patient is being followed in clinic
after discharge for further evaluation regarding closure
of PFO.

DISCUSSION
This case demonstrates how PFOs can be a contributing
cause of hypoxia in patients with underlying cardiovascular disease. Patients with significant right to left
shunting from PFOs usually present with hypoxia that
does not improve with increasing oxygen requirement.
Other symptoms include platypnea and orthodoxia,
both of which our patient also demonstrated. Diagnosis
of a PFO with shunting can be accomplished via a TEE
with bubble study.1 After diagnosis, treatment depends
on weighing the risks of cardiac surgery with the benefits
of improvement in hypoxia and quality of life. Research
is still being conducted on the definitive benefits of
surgical repairs of PFOs in patients with hypoxia.2 The
patient in this case continues to follow with structural
heart after discharge and is being evaluated for surgical
repair of his PFO, considering the severity of his shunt
symptoms, in hope to improve his quality of life.
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KEY POINTS
Patent foramen ovales (PFOs) can be a cause of
persistent hypoxia in patients when there is significant
right to left shunting. Research is still being conducted
on the value of closure of PFOs as a treatment for
persistent hypoxia.
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Shocked But Not Surprised: The Philly Cardioversion
Gillian Naro, MD, MEd1, Naman Upadhyay, MD1, Emilie Thompson, MD1, Tudor Sturzoiu, MD1
1. Division of Hospital Medicine, Department of Medicine Thomas Jefferson University Hospital, Philadelphia, PA

INTRODUCTION
Neuromuscular incapacitating devices, colloquially
known as ‘tasers’, are typically used by police and security
personnel as a non-lethal way to subdue combative
assailants. Unfortunately, there are times in the hospital
when patients can become assailants, thus potentially
necessitating the use of tasers to ensure the safety of
staff and other patients. Tasers come in several varieties.
However, those typically used by law enforcement have
a 50,000-V capacity and deliver 0.36 - 1.76 Joules of
energy per pulse, at a rate of ~20 pulses per second, via
two barbed projections1. This leads to incapacitation of
the assailant via the induction of fused muscle
contractions that preclude coordinated neuromuscular
inputs, thus inducing a near-tetanic state 2. In medicine,
we often use electricity in a coordinated manner to
convert dangerous cardiac arrhythmias back to normal
sinus rhythm. In this case, we discuss how a patient who
was admitted to the hospital in a sustained arrhythmia,
became an assailant. A taser was used to subdue him,
and we will examine how this theoretically may have
impacted his arrhythmia.

CASE
A patient with a past medical history of advanced heart
failure with reduced ejection fraction of 10% secondary
to methamphetamine use was admitted to the medical
intensive care unit for severe COVID-19 infection
resulting in hypoxic respiratory failure requiring
intubation. His acute respiratory condition stabilized,
and he was liberated from the ventilator. His oxygen
status continued to improve as he was weaned to 2L
nasal cannula, and he was transferred to a general
medicine telemetry service.
His hospital course was further complicated by
suspected in-hospital use of methamphetamines
resulting in atrial fibrillation with rapid ventricular
response with rates in the 150s. The patient reported
feeling “bad”, and he was noted to be diaphoretic and
agitated. He was started on a digoxin infusion and given
intravenous diuresis. As he experienced subjective
improvement with down trending heart rates, he asked
to leave the hospital against medical advice (AMA). On
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examination of the patient, he was unable to express
the risks of leaving the hospital and foregoing additional
medical interventions. With psychiatry input, patient
was deemed to lack capacity to leave AMA.
Patient then became angered, decannulated his
intravenous lines, removed his telemetry strips, and
attempted to leave the hospital room. He became very
aggressive with threats of violence to the medical staff,
so security was contacted. His condition visibly appeared
to deteriorate as he was in clear extremis, diaphoretic,
and weak. Even his screaming became more tired and
hoarse. Finally, after an hour of negotiation, the patient
lunged at the provider, requiring the security officer to
react by activating his taser and delivering a shock. He
was then injected with 5mg of intramuscular haloperidol
and placed in four-point restraints. The team was hopeful
that the delivery of electricity to his chest may have
restored sinus rhythm, but the patient remained in atrial
fibrillation when placed back on telemetry.

DISCUSSION
It has been previously posited that taser devices pose
minimal cardiac threat because of the depth of tissue
that must be penetrated to affect the heart, the relative
intensity of electrical energy required to activate
cardiac muscle as opposed to skeletal muscle, and the
different electric pulse widths required to activate
cardiac as opposed to skeletal muscle2. There has
been extensive original research assessing the cardiac
and even neurologic risk associated with taser devices
since their development, and this has also been
reviewed in the literature1.
Interestingly, it does appear that taser shocks can
influence cardiac activity, as was demonstrated in a
previous report outlining a pacemaker interrogation
that revealed the induction of rapid ventricular
conduction in a patient following a taser shock4.
Additionally, we were able to locate one case report of
atrial fibrillation induced in a patient with no history of
atrial fibrillation, normal electrolytes, and a structurally
normal heart following the application of a taser shock5.
In the case of our patient, there was a fleeting hope
among the care team that the taser shock could have
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successfully restored sinus rhythm via electrical
cardioversion, but this was revealed to not be the case
after he was back on telemetry after being subdued.
There are many reasons why this might be, but it seems
reasonable that inherent differences among different
brands of tasers may affect the potential of each unit to
influence myocardial conduction. Further, various
areas on the human body where this shock could be
applied, it stands to reason that there are many potential
physiologic effects of a taser shock that will not be
experienced. Additionally, the actual energy delivery
per taser shock is quite low, at around an average of 1
J per pulse among different units, and it is difficult to
quantify what additive effect the many shocks delivered
per second may have on myocardial conduction.
Research by Richard et al reports only a 22% success
rate with 50 J in external cardioversion in atrial
fibrillation, which is significantly higher than the average
J delivered per shock from a taser6,7,8. In a patient with
severe cardiomyopathy, even a coordinated shock
from a dedicated defibrillator may not be successful in
restoring sinus rhythm, so it is not entirely surprising
that a taser-mediated shock, which we fondly refer to
as a “Philly Cardioversion”, was unable to restore sinus
rhythm in this patient.
Although the authors would certainly prefer that no
additional humans undergo a taser shock, further
observation of the incidence of the resolution of
arrhythmias in the setting of taser shocks will continue
to elucidate the potential of these enforcement tools to
influence cardiac activity. Since tasers are designed to
provide a non-lethal shock, their mechanics would
ideally have very low risk myocardial involvement.
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A Confounding Case of Acute Hepatitis A
Andrea Molin, MD1, Michael Cheung, MD1, Timothy Kuchera, MD1
1. Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Figure 1: Liver Function Tests Through Hospitalization
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INTRODUCTION
Hepatitis A (HAV) is a picornavirus transmitted via
fecal-oral route that disproportionately affects
homeless persons, men who have sex with men, and
individuals who use intravenous drugs.1 Acute HAV
typically presents with nausea, vomiting, abdominal
pain, and fever. It is most commonly self-limited but
can progress to fulminant hepatic failure in less than
1% of cases.2 The following case is a unique presentation
of acute HAV infection requiring diagnostic dexterity
and critical thinking.

CASE DESCRIPTION
A 28-year-old male with a past medical history of opioid
use disorder and chronic hepatitis C (HCV) without
baseline evidence of cirrhosis who presented with
several days of fevers and lethargy. He denied abdominal
pain, nausea, vomiting, and diarrhea. The patient was
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Total Bilirubin

Direct Bilirubin

febrile to 103.4F and tachycardic to 145 bpm. Initial labs
were notable for WBC 4.3 B/L, HgB 11.0 g/dL, Plt 143
B/L, AST 136 IU/L, ALT 193 IU/L, and HCV PCR 7000
IU/L. He received broad spectrum antibiotics, fluid
resuscitation, and was admitted to general medicine.
Given his high-risk demographic, the HAV vaccine was
administered for primary prophylaxis.
Over the next 24 hours, fevers persisted despite
antibiotics. Blood cultures remained negative. An MRI
spine performed for back and neck pain was negative
for infection. The patient’s hepatic function panel
peaked at: ALP 270 IU/L, AST 2047 IU/L, ALT 2196 IU/L,
total bilirubin 6.3 IU/L, direct bilirubin 5.8 IU/L with
associated INR 1.15, PT 13.5 sec, PTT 38 sec (Figure 1).
Comprehensive infectious workup (Table 1) came back
negative other than a positive HAV IgM antibody. Since
the clinical interpretation of positive HAV IgM antibody
was unclear in the setting of recent vaccination, an
HAV viral PCR was ordered and returned positive,
confirming the diagnosis of acute hepatitis A.
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Table 1: Exhaustive Infectious Workup
L ab Nam e

Valu e

R e f e r e nc e R ang e

HAV Ab

r e ac tiv e

nonreactive

HAV IgM

r e ac tiv e

nonreactive

HAV RNA PCR

p o sitiv e

negative

Hepatitis B Surface Ab

nonreactive

nonreactive

Hepatitis B Surface Antigen

nonreactive

nonreactive

Hepatitis B Core Antibody

nonreactive

nonreactive

HCV Antibody

r e ac tiv e

nonreactive

HCV PCR VL

7 0 1 0 I U /m l; 6990 I U /m l

not detected

HIV Antibody/Antigen

nonreactive

nonreactive

HIV PCR

not detected

not detected

Varicella Zoster Virus IgG

p o sitiv e

negative

Varicella Zoster Virus PCR

<500 copies/ml

<500 copies/ml

Cytomegalovirus PCR

<100 IU/ml

<100 IU/ml

Herpes Simplex Virus 1 DNA PCR

<100 copies/ml

<100 copies/ml

Herpes Simplex Virus 2 DNA PCR

<100 copies/ml

<100 copies/ml

Ehrlichia chaffeensis IgG

<1:64

<1:64

Ehrlichia chaffeensis IgM

<1:20

<1:20

Anaplasmosis phagocytophilium IgG

<1:64

<1:64

Anaplasmosis phagocytophilium IgM

<1:20

<1:20

Epstein-Barr Virus EBNA IgG

p o sitiv e

negative

Epstein-Barr Virus VCA IgG

p o sitiv e

negative

Epstein-Barr Virus VCA IgM

p o sitiv e

negative

Epstein-Barr Virus DNA PCR

<200 copies/mL

<200 copies/mL

Epstein-Barr Virus DNA PCR

<2.3 log cps/ml

<2.3 log cps/ml

RNA PCR returned and confirmed the positive IgM was
due to acute HAV infection rather than vaccination.
In order to avoid confusion and ensure correct
diagnosis, this clinical case highlights the importance
of checking HAV IgM in anyone presenting with
potential infection prior to vaccination against HAV.
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DISCUSSION & CONCLUSIONS
The etiology of our patient’s acute illness was challenging
to diagnose due to several confounding variables. On
hospital day 1, he received a single antigen inactivated
HAV vaccine. On hospital day 7, his HAV IgM was positive.
We hypothesized that the positive HAV IgM antibody
represented either acute HAV infection or an antibody
response to recent immunization. Evidence suggests
that anti-HAV IgM is detected 2-3 weeks after administration of the single dose inactivated HAV vaccine.2 It
would be unusual for the patient to develop anti-HAV
IgM in the 7 day period between vaccination and testing.
The patient’s history of HCV also complicated the
diagnosis. He received past treatment for HCV, but
admission labs were indicative of treatment failure or
reinfection. Ultimately, HCV viral load remained stable,
reducing concern for acute HCV as the cause of his
presentation.
Finally, acute HIV and tick-borne illnesses were of
concern due to active IVDU and homelessness. However,
his HIV, ehrlichia, and lyme antibodies were negative.
The diagnosis of acute HAV was established when HAV
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ABSTRACT
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are
being prescribed increasingly more often for type 2
diabetes mellitus as well as heart failure. They have not
typically been associated with acute pancreatitis, but there
has been a steady flow of case reports implicating them
in acute pancreatitis over the years since they were initially
approved. Here, we present the case of an 82-year-old
woman with a past medical history of T2DM, COPD,
hyperlipidemia, a remote stroke, peripheral arterial disease,
and remote breast cancer now with recurrent localized
breast cancer on treatment with ademaciclib and letrozole
who presented to the emergency department with
abdominal pain, weakness, decreased oral intake, and
nausea and vomiting. These symptoms started two weeks
after the initiation of the SGLT-2 inhibitor empagliflozin for
her T2DM. Initial labs were notable for sodium of 129,
glucose of 409, a normal anion gap, beta hydroxybutyrate
of 4.6, serum creatinine of 0.92, calcium of 9.8, total
bilirubin of 3.0 with direct bilirubin 2.6, alkaline phosphatase
of 773, AST of 330, ALT of 446, lipase of 1,159, triglycerides
of 237, and leukocyte count of 4.9. Following admission,
CT and MRCP demonstrated pancreatitis with no
intrahepatic or extrahepatic ductal dilation, gallstones
choledocholithiasis, or other obvious etiology of her
presentation. Her symptoms improved with supportive
care following the discontinuation of her SGLT-2 inhibitor
and she was discharged to inpatient rehab shortly after
presentation. This case highlights the importance of
keeping the uncommon diagnosis of SGLT-2 inhibitor
associated pancreatitis in mind in patients who present
with acute pancreatitis.

INTRODUCTION
According to the Centers for Disease Control, the
prevalence of type 2 diabetes mellitus (T2DM) in 2020
was nearly 10.5%1. Given its overall burden and the range
of complications that can arise from long-term T2DM, it
makes sense that there continue to be emerging
therapies to treat it. One of the drug classes approved
within the last decade, sodium-glucose co-transporter 2
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(SGLT-2) inhibitors, function by reducing the reabsorption
of glucose at the level of the renal tubule, thus causing
lower blood glucose levels through therapeutic
glucosuria. It has been increasingly prescribed for T2DM
and was recently approved for the treatment of heart
failure with reduced ejection fraction even in the absence
of T2DM. Pancreatitis, which has been associated with
some classes of T2DM medications, is an uncommon
side effect of SGLT-2 inhibitors. Still, there have been a
few reports of SGLT-2 inhibitors induced pancreatitis
since their approval, and it is important to keep this side
effect in mind when prescribing these drugs for the first
time or when treating someone for acute pancreatitis in
the setting of recent initiation of an SGLT-2 inhibitor2-4.
Here, we present the case of an 82-year-old woman
who presented with subacute abdominal pain caused by
pancreatitis 30 days after initiation of the SGLT-2 inhibitor
empagliflozin in the setting of poorly controlled diabetes.

CASE REPORT
Our patient is an 82-year-old woman who presented to
the emergency department in January of 2021 with
almost 2 weeks of abdominal pain with radiation to her
back, weakness, and decreased oral intake. She had
also been experiencing nausea and vomiting for 3-4
days prior to admission. Her significant past medical
history included poorly controlled T2DM with recent
Hgb-A1C of 11.1%, COPD, a remote stroke, hyperlipidemia, peripheral artery disease, and two previous
episodes of breast cancer in 1994 and 2015 now with
recurrence. Her medications included metformin,
fluticasone/salmeterol, tiotropium, albuterol,
rosuvastatin, clopidogrel, lorazepam, abemaciclib and
letrozole. She was initiated on empagliflozin to optimize
the treatment of her T2DM on at the start of December
of 2020. Additionally, she was recently diagnosed with
recurrent estrogen receptor positive, progesterone
receptor positive, human epidermal growth factor
receptor-2 negative inflammatory breast cancer of the
right breast in November of 2020, at which time she
was initiated on abemaciclib and letrozole.
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On presentation, initial vital signs included a temperature
of 96.60F, pulse of 83 beats per minute, blood pressure
of 156/75 mmHg, respiratory rate of 18, and oxygen
saturation of 96% on room air. Physical examination
was significant for lethargy, dry mucous membranes,
diffuse abdominal tenderness without rebound or
guarding, and a firm right breast mass with dimpling of
the overlying skin. Initial labs were notable for a sodium
of 129, bicarbonate of 15 (baseline 18-20) with a normal
anion gap, serum creatinine of 0.92, glucose of 409,
calcium of 9.8, total bilirubin of 3.0 with direct bilirubin
2.6, alkaline phosphatase of 773, AST of 330, ALT of
446, beta hydroxybutyrate of 4.6, lactate of 1.4, lipase of
1,159, triglycerides of 237, leukocyte count of 4.9, and
hemoglobin of 11.3. CT of the abdomen and pelvis
without contrast demonstrated peripancreatic fat
stranding and edema consistent with acute
uncomplicated pancreatitis. Notably, it also showed a
normal liver, normal bile ducts without dilation, and a
normal gallbladder without gallstones. She had held
most of her medications on her own prior to
presentation due to a concern that they could be related
to her symptoms. The following day, ultrasound of the
abdomen confirmed absence of cholelithiasis and
choledocholithiasis with normal caliber intrahepatic
and extrahepatic biliary ducts including the common
bile duct as well as a normal gallbladder without stones
or edema. It also showed signs of acute pancreatitis,
though this was better imaged on the CT scan from the
prior day. Due to concern for an occult obstructive
lesion in the biliary system in the setting of persistently
high ALP, AST, ALT, and bilirubin in the setting of
malignancy, she was sent for magnetic resonance
imaging with MRCP, which demonstrated no
intrahepatic or extrahepatic biliary ductal dilatation and
again confirmed no cholelithiasis or choledocholithiasis. It also visualized a 0.7 cm intraductal papillary
mucinous neoplasm, which was slightly increased in
size since the last time it was imaged in 2012. At this
point, her symptoms had improved significantly since
her SGLT-2 inhibitor was held, but her liver function
tests (LFTs) were persistently elevated. As such, she
underwent esophagogastroduodenoscopy with
endoscopic ultrasound, which showed diffuse
thickening of common hepatic duct and common bile
duct walls without dilation or stones. In consultation
with GI, it was determined that her persistently elevated
LFTs were in the setting of acute pancreatitis, and they
were expected to trend down over the next days to
weeks. The patient continued to improve symptomatically, and her LFTs did trend down before her eventual
discharge to inpatient rehabilitation.
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DISCUSSION
SGLT-2 inhibitors have been implicated in drug-induced
pancreatitis in a few case reports2-4. A recent review
aggregated case reports of SGLT2-associated
pancreatitis and found that four reports were associated
with canagliflozin, two with empagliflozin, and one
with dapagliflozin3. Since that paper was published,
another case report for empagliflozin-induced
pancreatitis has been published4. Our case report is
the fourth that we were able to find for empagliflozin.
In the previous review, the mean time interval from
initiation of the SGLT-2 inhibitor to diagnosis of
pancreatitis was 39 days, which falls in line with the
time interval observed in this case – 30 days.
Our patient presented with clinical, laboratory and
imaging findings of acute uncomplicated pancreatitis.
In the absence of any of the other classic causes of
pancreatitis (including alcoholism, gallstones,
obstructive mass lesion in the setting of malignancy,
and hypertriglyceridemia) and the recent initiation of
an SGLT-2 inhibitor, we believe drug-induced
pancreatitis to be the most likely cause of her
presentation. Letrozole and abemaceclib were also
recently initiated, but these are less likely to be causes
of pancreatitis. We were not able to find any case
reports of pancreatitis associated with these two
agents, and in fact, letrozole has been prescribed as an
alternative to tamoxifen in a number of cases where
tamoxifen was implicated in pancreatitis5-7.
The mechanism for the development of pancreatitis is
unknown with regards to this drug class, which has
only been associated with pancreatitis in a few case
reports. It is becoming more apparent that SGLT-2
inhibitors have broader in vivo actions than just SGLT-2
inhibition in renal tubular cells, and it is possible that
some of these effects are responsible for the
development of pancreatitis. The range of conditions
for which SGLT-2 inhibitors are approved is expanding,
such that they will be prescribed increasingly more
commonly over the next years, which could lend
further insight into the extent of their physiologic
actions.
This case report highlights the importance of keeping
the rather uncommon diagnosis of SGLT-2-induced
pancreatitis in mind when treating a patient with acute
pancreatitis, as timely discontinuation of the SGLT-2
inhibitor caused improvement of symptoms in all case
reports that we reviewed.
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"Not fragile like a flower, fragile like a bomb" – Heping Sheng, MD
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INTRODUCTION

CASE PRESENTATION

It is well known that hereditary or acquired methemoglobinemia can cause hypoxia due to the oxidation of heme,
which impairs its ability to offload oxygen (Figures 1 & 2),
and that acquired methemoglobinemia is most often
caused by exposure to drugs and toxins that oxidize
hemoglobin to methemoglobin, directly or indirectly1.
Recently, a few case reports have highlighted methemoglobinemia in patients with COVID-19 pneumonia. Some
of these reports were due to treatment with hydroxychloroquine and others from unidentifiable causes2-4. We
present a case in which a patient with COVID-19
pneumonia was diagnosed with methemoglobinemia
and acute hemolysis from G6PD deficiency in the setting
of worsening hypoxia after receiving treatment with
dexamethasone, remdesivir, and high-dose vitamin C.

A 32-year-old African American male with no significant
past medical history presented to the emergency room
with exertional shortness of breath and non-productive
cough for 6 days. He was febrile to 103°F and had an
oxygen saturation of 91% on room air. He had no evidence
of crackles or wheezes on lung auscultation, but his chest
x-ray showed bilateral patchy opacities and a COVID-19
nasopharyngeal swab was positive. He was admitted and
started on Remdesivir and dexamethasone 6 mg/day. On
hospital day (HD) 2, he enrolled in a COVID high-dose
vitamin C trial where he was randomized to the treatment
arm and received 34g of vitamin C (0.3g/kg) IV on HD 2
and 68g (0.6g/kg) IV on HD 3. He was removed from the
trial on HD 4 for worsening hypoxia. On HD 5, his oxygen
saturation was 80% on 15L of oxygen. Despite his low
oxygen saturation, he had no shortness of breath or
increased work of breathing. An arterial blood gas while
on 15L showed: pH 7.39, PaCO 2 43 mmHg, PaO 2 110
mmHg, measured O2 saturation 88%, and calculated O2
saturation 99%. He was subsequently transferred to the
intensive care unit for closer monitoring.
Due to the discrepancy between his pulse oximeter
(SpO2) and arterial oxygen saturation (PaO2), a co-oximetry
panel was sent. This revealed a mildly elevated
methemoglobin level of 8.1%. Notably, his hemoglobin
had declined from 13.7 on admission to 6.8 g/dL by HD
8, and his creatinine climbed to 3.6 mg/dL from 1.0 mg/
dL. In addition to methemoglobinemia, he was found to
have a non-immune hemolysis, and review of his
peripheral blood smear showed bite and blister cells with
the presence of Heinz bodies. A serum G6PD level
obtained at the time of active hemolysis was inappropriately low at 3.5 U/g Hg. Hematology recommended
treatment of his methemoglobinemia with 1.5g of
vitamin C every 8 hours for a total of 4 days, which
improved his methemoglobin level to 4%. Methylene
blue was not used given his diagnosis of G6PD deficiency
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and his methemoglobin level was only mildly elevated.
Methylene blue is considered in patients with moderate
to severe elevations in methemoglogin (>20-30%). By HD
8, he was maintaining 95-100% oxygen saturation on
room air, and his hemoglobin eventually recovered to 12
g/dL one month later without additional treatment (see
Figure 3 for complete timeline of events).

DISCUSSION
Undoubtedly, this patient’s hypoxia from COVID-19
pneumonia was exacerbated by methemoglobinemia
and acute hemolysis from underlying G6PD deficiency,
but the cause of the methemoglobinemia remains
unclear.
Since he was only exposed to three medications
(remdesivir, dexamethasone, and high-dose vitamin C),
there is concern that one of these pharmacotherapies
acted as an oxidative stressor inducing both methemoglobinemia and hemolytic anemia. While physiologic
doses of vitamin C act as a reducing agent, there are
case reports that suggest supraphysiologic doses of
vitamin C (30g or more) can act as an oxidizing agent.
This mechanism is due to the production of hydrogen
peroxide as a byproduct of ascorbic acid in high serum
concentrations cycling between its ionized and radical
forms, allowing hydrogen peroxide to oxidize
hemoglobin and cause lipid peroxidation of the cell
membrane leading to intravascular hemolysis5.
It is worth noting that there is another case report similar
to ours (but without the use of Vitamin C) where no
known inducer of methemoglobinemia was identified
and the authors discussed the possibility of COVID-19
acting as an oxidative stressor itself like that of other viral
infections that produce reactive oxygen and nitrogen
species3. Thus, it is also possible that the viral insult may
have contributed to the development of this patient’s
methemoglobinemia.
Despite the unknown etiology of our patient’s methemoglobinemia, this case emphasizes the importance of
keeping a broad differential and recognizing the
discrepancy between the patient’s SpO 2 , PaO 2 , and
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clinical exam. It is imperative to recognize this abnormality
and obtain an arterial co-oximetry panel once erroneous
causes of this discordance are ruled out such as: poor
probe positioning, hypothermia, and acrylic/painted
nails. It also has important implications for the
management of COVID-19, especially when considering
treatments known to cause methemoglobinemia or
trigger hemolysis in G6PD deficiency, like hydroxychloroquine and supraphysiologic doses of vitamin C.

KEY POINTS
•

It is important to keep a broad differential for
hypoxia in the setting of COVID-19 pneumonia
and recognize discrepancies between SpO2, PaO2,
and the clinical exam.

•

It is imperative to recognize this abnormality and
obtain an arterial co-oximetry panel once
erroneous causes of discordance are ruled out
such as: poor probe positioning, hypothermia, and
acrylic/painted nails.

•

Although vitamin C is a treatment for mild
methemoglobinemia due to its reduction potential,
it has been reported to be an oxidizing agent at
supraphysiologic doses (>30 grams).
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Spontaneous Tumor Lysis Syndrome in
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INTRODUCTION
Tumor lysis syndrome (TLS) is an oncologic emergency
that is caused by electrolyte derangements from the
lysis of malignant tumor cells. The syndrome consists
of several laborator y abnormalities including
hyperuricemia, hyperkalemia, hyperphosphatemia, and
hypocalcemia1,2. When these lab findings are associated
with end-organ damage such as acute renal failure,
seizures, or cardiac dysrhythmias amongst others, it is
known as clinical TLS 3 . TLS is more commonly
associated with hematological malignancies given their
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tendency of rapid cellular turnover. The most common
culprits include acute lymphocytic leukemia and
Burkitt’s lymphoma. It is, however, quite rare for TLS to
occur secondary to a solid malignancy4. In fact, only 74
cases of solid-tumor TLS have been reported between
1977-20115. Furthermore, in case of solid tumors, they
are almost always related to administration of cytotoxic
chemotherapy leading to rapid cell death. Therefore,
the case described here of spontaneous TLS leading to
atrial flutter in an 89-year-old female with large pelvic
mass is a rare presentation.
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CASE REPORT
An 89-year-old female arrived at the ED on the
recommendation of her outpatient provider after a lab
test showed hyperkalemia. For a few months before this,
she had been noticing fatigue, bloating, and increased
abdominal girth. She was referred to gynecologic
oncology about a month prior to her presentation who
performed an ultrasound which showed a very large
complex multiloculated, complex, cystic mass that
measured 24 x 13 x 28 cm overtaking the entire pelvic
and abdominal region which prompted the decision to
carry out an exploratory laparotomy. The preoperative
lab work was significant for a potassium level of 6.0, for
which she was asked to seek care immediately.
At presentation to the emergency department, her
heart rate was 145, blood pressure 127/79, respiratory
rate 20, and oxygen saturation of 99%. She was
uncomfortable with diffuse wheezing, profound
abdominal distention, and 2+ bilateral lower edema. An
EKG carried out at the time exhibited atrial flutter with a
right bundle branch block. Prior EKGs had been normal
sinus rhythm and the patient denied any history of
rhythm disorders. Initial labs were significant for
potassium 5.7, BUN 105, creatinine 4.23, calcium 8.0,
LDH 526, urate 15.7, and phosphate of 8.2. She was
given diltiazem, which decreased her rate to the low
100’s. CT abdomen and pelvic mass showed that the
mass was significantly displacing the abdominal
structures including vasculature, but no hydronephrosis
was present (Figure 1). She was admitted to the inpatient
service for further management.
Patient’s hyperkalemia was temporized with administration of insulin and dextrose along with albuterol and
multiple doses of calcium gluconate. Upon admission,
she was started on bicarbonate drip at 80ml/hr and was
dosed several times with intravenous Lasix. However,
her urine output remained poor with only 200 ml over
the course of the first 24 hours of admission. Her acute
renal failure was likely precipitated by a combination of
TLS and mass effect. Given the significant elevation in
her uric acid level 3 mg IV rasburicase was also
administered on admission and was redosed 24 hours
later. Despite the above interventions, the patient's
electrolytes abnormalities and her renal function
worsened. Dialysis was considered as a possible
management option and nephrology was consulted,
however, given the overall poor prognosis the decision
was made to abort this effort in discussion with the
family. At this point her mental status acutely worsened,
and she became lethargic, only intermittently opening
her eyes during discussions. Goals of care discussions
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were initiated with her family, who ultimately decided
on comfort measures following which she was
discharged to inpatient hospice.

DISCUSSION
Tumor lysis syndrome is one of the true oncologic
emergencies precipitated by the release of intracellular
components of malignant cells into the bloodstream
often following initiation of chemotherapy. TLS is
usually defined by the Cairo and Bishop's Classification
System which requires at least two of the following
metabolic derangement -- potassium ≥6 mmol/L or
25% increase from baseline; phosphorus ≥4.6 mg/dL or
25% increase from baseline; calcium ≤7.0 mg/dL or 25%
decrease from baseline; uric acid ≥8.0 mg/dL or 25%
increase from baseline-- for the diagnosis to be made.
If the above-mentioned criteria is fulfilled, then the
process is characterized as laboratory TLS3. If any end
organ damage is present in addition to the electrolyte
abnormalities, including but not limited to acute kidney
injury and cardiac dysrhythmias, then diagnosis of
clinical TLS can be made 1,3. Our patient made the
criteria for both laboratory and clinical TLS given her
increased potassium, phosphate, uric acid along with
acute kidney injury as evidenced by increased creatinine
and oliguria along with new onset atrial flutter.
Given TLS is a consequence of rapid destruction of
malignant cells, it is often associated with rapidly
proliferating and chemosensitive hematological
malignancies. Although they more commonly occur
following chemotherapy, TLS can also develop in
absence of any intervention. In such cases it is known
as spontaneous TLS. This is often observed with
particularly aggressive hematological cancers including
acute lymphocytic leukemia, Burkitt’s lymphoma,
Diffuse large B-Cell lymphoma amongst others 4,6 .
Although the exact reason for this is not clear, TLS is
quite rare in solid tumors and cases of spontaneous
solid tumor TLS are even more scarce 6 . As stated
previously, only 74 cases of solid-tumor TLS have been
reported between 1977-2011 with only a fraction of
them being spontaneous5. Therefore, the presentation
of severe TLS in this patient with gynecologic tumor in
absence of chemotherapy is quite unique. It is likely this
was precipitated by the heavy tumor bulk in the context
of other risk factors including advanced age and overall
poor health of the patient4.
Another interesting part of this presentation is the
development of new onset atrial flutter in the setting of
hyperkalemia caused by her TLS. The ECG changes
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associated with hyperkalemia have been well-described
and include peaking of T waves, P-wave flattening, and
QRS complex widening. Arrhythmias less commonly
seen include atrial fibrillation and even asystole or
ventricular fibrillation in severe cases. Atrial flutter, as
seen in our patient, rarely occurs during hyperkalemia
with only two previously described cases in our
literature search7. In this patient’s case, her risk for
arrhythmia was likely increased by the presumed rapid
onset of hyperkalemia along with her concurrent
hypocalcemia, which can potentiate the effects of
hyperkalemia.
Treatment of TLS is geared towards addressing the
electrolytes derangements. The mainstay of treatment
remains fluid administration with close monitoring of
urine output. The rate of fluids is adjusted to maintain
the urine output between 80 to 100 ml/hr2,8. If that
level of output is not reached, diuretics are utilized to
increase urine flow. Fluid administration ensures
increased renal blood flow with subsequent increase in
GFR and upregulation of elimination of potassium,
phosphorous, and uric acid. In situations where,
appropriate urinary output cannot be achieved, as
might be the case in patients with chronic kidney
disease, dialysis is indicated. Other management
options are geared towards specific electrolyte
derangement. Rasburicase, which upregulates
transformation of uric acid into allantoin which is
highly soluble in water thus facilitating urinary excretion
is used to treat acute rise in uric acid. Allopurinol, a
xanthine oxidase inhibitor, which block conversion of
xanthine to uric acid can be used concurrently to
prevent accumulation of uric acid2,8. Similarly, while
hyperkalemia is more definitively addressed through
urinary excretion or dialysis, intravascular potassium
levels can be temporized through administration of
insulin. Calcium, which is often depleted due to
binding by phosphate is repleted through of addition
of calcium gluconate.
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CONCLUSION
Tumor lysis syndrome (TLS) is an oncologic emergency
that is caused by electrolyte derangements from the
lysis of malignant tumor cells resulting in laboratory
abnormalities including hyperuricemia, hyperkalemia,
hyperphosphatemia, and hypocalcemia. It is often
associated with rapidly proliferating and chemosensitive
hematological malignancies often following cytotoxic
treatment. The case presented in this paper where TLS
occurred not only with solid tumor but spontaneously
in absence of any interventions is a rare presentation.
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Figure 1: Computed tomography (CT) chest revealing tumor invasion with intraluminal thrombus of the right superior pulmonic vein (A and B). Bronchoscopy revealing luminal
compromise (C) prompting tracheal stent placement (D). Positron emission tomography (PET) imaging ultimately showed increased tracer uptake concerning for malignancy (E).

INTRODUCTION
Basal Cell Adenocarcinoma (BCAC) is a rare malignancy,
only accounting for approximately 2% of all salivary
neoplasms1. Considered the malignant counterpart of
basal cell adenoma, it most commonly presents at 60
years of age without gender predilection. Sites of
involvement frequently includes the parotid gland, but
sites in the minor salivary glands, nasopharynx, buccal
mucosa, and tongue have also been reported2,3. Often
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regarded as an indolent malignancy, BCAC can
occasionally cause invasive disease and infrequently,
metastatic disease 2 . Among all solid tumors,
endobronchial metastases is quite a rare occurrence,
contributing to approximately 4% of endobronchial
biopsies4. Most common sites of metastases in BCAC
include cervical lymph nodes with sparse reports of
pulmonary, hepatic and cutaneous involvement5. We
present a case of endobronchial metastases from
BCAC of the base of the tongue.
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CASE PRESENTATION & OUTCOME

DISCUSSION & KEY POINTS

A 76-year-old male with a past medical history of BCAC
who underwent right tongue base excision with bilateral
neck dissection followed by adjuvant radiotherapy in
2018 and prostate cancer treated with radiotherapy
who presented with a one-day history of hemoptysis.
Two weeks prior to initial presentation, he underwent a
CT-guided lung biopsy for a right upper lobe nodule
that was nondiagnostic. There was concern that his
hemoptysis was related to his recent procedure, so he
was transferred to the academic medical center for
further evaluation.

The management of BCAC, as with all salivary gland
neoplasms, is particularly challenging due to the
phenotypic heterogeneity and low clinical incidence.
The most common strategy includes surgical resection
with adjuvant radiotherapy. While distant metastases is
an uncommon recurrence, local recurrence is quite
common despite tumor-free surgical margins with rates
of upward to 50%2. Chemotherapy has been found to be
of limited use, predominately in the setting of recurrent
or metastatic disease. Currently, there are no National
Comprehensive Care Network (NCCN) recommendations for specific regimens. The most common agents
include cisplatin, doxorubicin with either 5-fluorouracil
or cyclophosphamide. However, no regimen has
produced significant and reproducible improvements in
overall survival or disease-free survival6.

On presentation, the patient felt well overall and had
not experienced any additional occurrences of
hemoptysis. Vital signs were stable, and physical
examination was significant for decreased breath
sounds in the right lower lung field. CT chest with
contrast was performed and revealed an enlarging
mediastinal and right infra-hilar lymph node causing
severe stenosis of the bronchus intermedius, right
middle, and right lower lobe bronchus. Findings also
included direct invasion with an intraluminal thrombus
of the right superior pulmonic vein (Figures 1A, 1B).
On hospital day 2, patient underwent bronchoscopy
that revealed extensive endobronchial tumor
involvement of the bronchus intermedius resulting in
approximately 80% luminal compromise (Figure 1C).
Tumor debulking was performed as well as tracheal
stent placement (Figure 1D). Patient was discharged
following the procedure, and an outpatient PET scan
confirmed malignant involvement (Figure 1E).
Pathology of the endobronchial mass revealed a poorly
differentiated basaloid epithelial neoplasm that was
morphologically similar the prior tongue biopsy. Of
note, histology revealed an exceptionally high
proliferation index (Ki67 > 90%). Comprehensive
genomic profiling did not reveal any potential targeted
therapies. After discussion with the multidisciplinary
tumor board, the decision was made to pursue palliative
radiotherapy followed by pembrolizumab monotherapy.
The patient expired at home approximately two months
after initial diagnosis.

This case demonstrates several unique features. This
patient did not experience local recurrence, but rather
distant metastasis to a novel location. Also, this patient
featured an exceptionally high proliferation index,
indicating that BCAC has the potential for clinical
heterogeneity. Finally, this case highlights the need for
further research into the role of imaging surveillance
during remission.
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REFLECTION
Point-of-care ultrasonography (POCUS) is defined as
the acquisition and interpretation of ultrasonographic
images generated by the clinician at the bedside. The
advent of handheld machines has increased access
and practical application of ultrasound technology in
internal medicine training and medical education. The
most common system involves a single portable
ultrasound probe that connects to a smartphone or
tablet, and storage of images are stored via cloud-based
technology. We discuss our experience with POCUS
using handheld ultrasound machines in the Thomas
Jefferson University Hospital academic setting.
There are several benefits to having a handheld
ultrasound machine as an Internal medicine resident.
Immediate access to ultrasound technology has
advantages in many settings, but especially in emergent
settings such as rapid response alerts with critically ill
patients in emergent situations. Specifically, POCUS
imaging lung views (B-lines, pleural effusions, lung
sliding, hepatization), global heart function, IVC collapsibility, vascular access are very helpful. In comparison,
the process of moving the department ultrasound
machine to the scene of a rapid response alert can take
up to 10 minutes, assuming a machine is available. The
clinical applications of POCUS as an adjunct to the
physical exam and auscultation with a stethoscope has
been emphasized by national groups; POCUS
integration into diagnostic pathways allows for
immediate visualization and results while avoiding
radiation and high costs. There is an added benefit of
increasing face to face time and direct patient care.
The ability to store imaging on cloud services, which is
a common service for the handheld ultrasound
machines, also provides an opportunity for educational
review and comparison with reference images.
An example of the use of POCUS as an Internal
medicine resident: I responded to a rapid response
alert to the dialysis unit, which is a setting in the hospital
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that lacks many of the resources of the wards or critical
care units. The alert was called for a 50 year old male
in respiratory distress. He was admitted for hyperkalemia
and he has a past medical history of end stage renal
disease requiring thrice weekly dialysis as well as
compensated heart failure. This was his first dialysis
session after being admitted for hyperkalemia. The
patient was feeling very short of breath and anxious.
Chest x-ray was ordered but would take 10 minutes to
arrive. The initial impression of the responders was that
given the medical history, the patient was volume
overloaded and the respiratory distress could be from
flash pulmonary edema. On my exam, ultrasound of
the lungs demonstrated only A-lines and normal lung
sliding, with no B-lines or pleural effusions. In addition
to the poor air movement and lack of significant rales
on auscultation, the differential changed and favored
bronchospasm. Treatment was started with albuterolipratropium. Later, chest XR confirmed the POCUS
findings. Soon, the patient also started breaking out in
an urticarial rash and continued shortness of breath
with wheezing. Dialysis was stopped and he was
treated with epinephrine, intravenous steroids, and
antihistamines. Urgent labs and vascular access were
also obtained by ultrasound guided venous access.
Later we found that the patient was having an allergy to
the dialysis filter, causing an anaphylactic reaction. The
use of POCUS enabled immediate diagnostic
information that changed our differential and prompted
different treatment. Especially with the finding that the
dialysis filter had been the reason for decompensation,
if the original working diagnosis of flash pulmonary
edema and volume overload had led to increasing the
ultrafiltration rate on dialysis, then the patient could
have further decompensated.
There are also barriers and disadvantages to use of
handheld ultrasound machines in the inpatient setting.
Unless trained, residents should not rely on POCUS in
clinical decision making; it should only be used for
educational purposes. What you see on an educational
scan can prompt ordering “formal” imaging though.
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Owning the machine alone doesn’t replace an
ultrasound tech, radiologist, and specialist experience.
The opportunity to receive formal mentorship can be
limited by faculty availability and access to the
machines. The cost of the machine can also be
prohibitive for individuals to purchase, ranging from
$2000 to $5000.
The following clinical images serve as an example of
resident utilization of POCUS devices: cardiac imaging
of heart failure secondary to chronic hypertension
(Figure A), abdominal imaging of large volume ascites
in alcoholic cirrhosis (Figure B), retroperitoneal
ultrasound of hydronephrosis in a patient with acute
renal failure (Figure C), and vascular imaging revealing
thrombus in proximal brachial vein of right upper arm
using biplane imaging (simultaneous longitudinal and
transverse views) (Figure D).
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The Laws of the Dead
Gillian Naro, MD MEd and Marie-Laure Flamer, MD

George Washington suddenly fell ill with a sore throat
and labored breathing at his estate in 1799. Initial
management consisted of a "mixture of molasses,
vinegar and butter," that was followed by “sage, tea and
vinegar.” With no signs of clinical improvement, his
doctors were called to his bedside. As was standard
medical care at the time and thought to be beneficial
in various afflictions, he was “bleed” more than 2L of
blood in an attempt to restore his good health. The
three doctors overseeing the bleeding process noticed
the General become weaker despite their best efforts.
His breathing became more labored and he passed
shortly after his treatment.
Since 1799 medicine has evolved. Treatments, like
“bleeding” or bloodletting, were researched for
effectiveness and weighed against potential harms.
Finding generally poor outcomes associated with the
treatment, the practice was abandoned and is no
longer used in modern medicine. In fact, many
treatment methodologies that were once accepted
by the medical community as the standard of care
even a few decades ago, have fallen out of favor today
in the wake of ongoing research and discovery.
As a modern physicians, we have the benefit of
hindsight, an ever expanding knowledge base and a
library of publications in every specialty to inform our
practice today. The medical community has
documented epidemics through incidence spikes
recorded in collected data, thus allowing research to
meet the communal need for intervention. There is
one epidemic, however, for which research is stifled.
In the particular case, modern interventions are largely
agreed upon to ensure patient safety, but are blocked
from practice. Movement on this particular public
health ailment has been halted; modern medicine and
lawful intercession cannot move forward. This unique
plague is the gun violence epidemic.
We have seen rates of gun violence escalate nationally
at remarkable rates. Unlike other epidemics, data
gathering is difficult largely due to an amendment to
a spending bill that has restricted the Centers for
Disease Control from funding research on gun deaths
and injuries since 1996. Physicians agree that the rise
in gun violence should be viewed as a national
epidemic. Organized medical groups, such as the
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American College of Physicians, have put out position
papers urging for research, legislative change, and for
gun violence to formally be labeled and managed as
an epidemic. Unlike generations before us who have
observed outcomes, collected data, researched,
analyzed, and adjusted practice to be evidence based
as to minimize harm, as a country we have instead
chosen to turn to a 250 year old document to be our
absolute guide on our practice.
General Washington’s cause of death has been
extensively reviewed in the literature for centuries.
Publications use the evidence recorded at the time
and weighed that against the growth in understanding
of the modern medical community. Advancements in
strategies to better diagnose, predict outcomes and
treat have shifted our understanding of the underlying
pathology from what those bedside doctors had
available to them two centuries ago. It is now believed
that Washington suffered from acute epiglottitis and
that the management of bloodletting hastened
Washington’s death significantly.
Despite constraints on collecting data, the science
around gun violence while limited, has persisted. We
see study after study informing the public that gun
violence is increasing. We have evidence supported
models for intervention strategies. Research has shown
us that age limits, assault rifle bans, and universal
background checks could be manages to manage this
epidemic. Why do we follow evidence based guidelines
in all other aspects of medical and epidemic
interventions except for the issue of gun violence?
Why is this the pathology that we refer back to the
practices of 250 years ago?
Washington’s contemporary and namesake of our
hospital and university, Thomas Jefferson, was among
the authors of the very document we use to dictate
our modern management of gun violence: The United
States Constitution. Yet even he would disagree with
this strategy of rejecting modern advancements and
evolving practices in the name of the tradition and
loyalty to the constitution. In 1789, Thomas Jefferson
wrote to his friend James Madison on the question of
whether one generation of men has the right to preside
over another.
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He wrote:
“I suppose [this] to be self- evident, ‘that the earth
belongs in usufruct to the living’: that the dead have
neither powers nor rights over it…On similar ground it
may be proved that no society can make a perpetual
constitution, or even a perpetual law. The earth belongs
always to the living generation.” (Jefferson, 1789)
Jefferson advocates for renewed reflection, research,
and change with each new generation. Similar to
medicine in which the field and guidelines are always
changing with new generations of scientists and
assumed new understandings, so too should we
update our societal practices and laws with the
growing body of knowledge.
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If Washington presented to a modern hospital today
we would have been diagnosed with acute epiglottitis
with radiographic imaging, and treated with
appropriate antibiotics. The management for his fatal
pathology has evolved from bloodletting. How much
more blood needs to be shed as a result of the gun
violence epidemic until we acknowledge our current
laws are causing harm. It is time to change. We can
no longer let the laws and practices of the dead rule
over the living.
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